Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma

被引:101
作者
Lokhorst, Henk M. [1 ]
Schmidt-Wolf, Ingo [2 ]
Sonneveld, Pieter [1 ]
van der Holt, Bronno [1 ]
Martin, Hans [2 ]
Barge, Rene [1 ]
Bertsch, Uta [2 ]
Schlenzka, Jana [2 ]
Bos, Gerard M. J. [1 ]
Croockewit, Sandra [1 ]
Zweegman, Sonja [1 ]
Breitkreutz, Iris [2 ]
Joosten, Peter [1 ]
Scheid, Christof [2 ]
van Marwijk-Kooy, Marinus [1 ]
Salwender, Hans-Juergen [2 ]
van Oers, Marinus H. J. [1 ]
Schaafsma, Ron [1 ]
Naumann, Ralph [2 ]
Sinnige, Harm [1 ]
Blau, Igor [2 ]
Delforge, Michel [1 ]
de Weerdt, Okke [1 ]
Wijermans, Pierre [1 ]
Wittebol, Shulamiet [1 ]
Duersen, Ulrich [2 ]
Vellenga, Edo [1 ]
Goldschmidt, Hartmut [2 ]
机构
[1] Dutch Belgian Hematooncol Cooperat Grp HOVON, Amsterdam, Netherlands
[2] German GMMG, Heidelberg, Germany
关键词
thalidomide; untreated multiple myeloma;
D O I
10.3324/haematol.11644
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In the prospective phase 3 HOVON-50/GMMG-1-1D3 trial, patients randomized to TAD (thalidomide, doxorubicin, dexamethasone) had a significantly higher response rate (at least PR) after induction compared with patients randomized to VAD (vincristine, adriamycin, dexamethasone, 72% vs. 54%, p<0.001). Complete remission (CR) and very good partial remission (VGPR) were also higher afterTAD. After High Dose melphalan 200mg/m(2) response was comparable in both arms, 76% and 79% respectively. However, CR plus VGPR were significantly higher in the patients randomized to TAD (49% vs. 32%, p<0.001). CTC grade 3-4 adverse events were similar in both arms.
引用
收藏
页码:124 / 127
页数:4
相关论文
共 20 条
[11]   Stem-cell transplantation in multiple myeloma [J].
Harousseau, JL ;
Moreau, P ;
Attal, M ;
Facon, T ;
Avet-Loiseau, H .
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2005, 18 (04) :603-618
[12]   Role of VAD in the initial treatment of multiple myeloma [J].
Lane, SW ;
Gill, D ;
Mollee, PN .
BLOOD, 2005, 106 (10) :3674-3674
[13]   Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy [J].
Minnema, MC ;
Breitkreutz, I ;
Auwerda, JJA ;
van der Holt, B ;
Cremer, FW ;
van Marion, AMW ;
Westveer, PHM ;
Sonneveld, P ;
Goldschmidt, H ;
Lokhorst, HM .
LEUKEMIA, 2004, 18 (12) :2044-2046
[14]   PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma [J].
Oakervee, HE ;
Popat, R ;
Curry, N ;
Smith, P ;
Morris, C ;
Drake, M ;
Agrawal, S ;
Stec, J ;
Schenkein, D ;
Esseltine, DL ;
Cavenagh, JD .
BRITISH JOURNAL OF HAEMATOLOGY, 2005, 129 (06) :755-762
[15]   Effect of complete response on outcome following autologous stem cell transplantation for myeloma [J].
Rajkumar, SV ;
Fonseca, R ;
Dispenzieri, A ;
Lacy, MQ ;
Witzig, TE ;
Lust, JA ;
Larson, D ;
Therneau, TM ;
Kyle, RA ;
Litzow, MR ;
Greipp, PR ;
Gertz, MA .
BONE MARROW TRANSPLANTATION, 2000, 26 (09) :979-983
[16]   Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma [J].
Rajkumar, SV ;
Hayman, SR ;
Lacy, MQ ;
Dispenzieri, A ;
Geyer, SM ;
Kabat, B ;
Zeldenrust, SR ;
Kumar, S ;
Greipp, PR ;
Fonseca, R ;
Lust, JA ;
Russell, SJ ;
Kyle, RA ;
Witzig, TE ;
Gertz, MA .
BLOOD, 2005, 106 (13) :4050-4053
[17]   Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma [J].
Rajkumar, SV ;
Hayman, S ;
Gertz, MA ;
Dispenzieri, A ;
Lacy, MQ ;
Greipp, PR ;
Geyer, S ;
Iturria, N ;
Fonseca, R ;
Lust, JA ;
Kyle, RA ;
Witzig, TE .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4319-4323
[18]   Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study [J].
Segeren, CM ;
Sonneveld, P ;
van der Holt, B ;
Vellenga, E ;
Croockewit, AJ ;
Verhoef, GEG ;
Cornelissen, JJ ;
Schaafsma, MR ;
van Oers, MHJ ;
Wijermans, PW ;
Fibbe, WE ;
Wittebol, S ;
Schouten, HC ;
Kooy, MV ;
Biesma, DH ;
Baars, JW ;
Slater, R ;
Steijaert, MMC ;
Buijt, I ;
Lokhorst, HM .
BLOOD, 2003, 101 (06) :2144-2151
[19]   Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma [J].
Segeren, CM ;
Sonneveld, P ;
van der Holt, B ;
Baars, JW ;
Biesma, DH ;
Cornellissen, JJ ;
Croockewit, AJ ;
Dekker, AW ;
Fibbe, WE ;
Löwenberg, B ;
Kooy, MV ;
van Oers, MHJ ;
Richel, DJ ;
Schouten, HC ;
Vellenga, E ;
Verhoef, GEG ;
Wijermans, PW ;
Wittebol, S ;
Lokhorst, HM .
BRITISH JOURNAL OF HAEMATOLOGY, 1999, 105 (01) :127-130
[20]   Thalidomide alone or with dexamethasone for previously untreated multiple myeloma [J].
Weber, D ;
Rankin, K ;
Gavino, M ;
Delasalle, K ;
Alexanian, R .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (01) :16-19